1. Home
  2.  » Pipeline

Going to the heart of shared molecular etiologies with rare primary indications

Our AI boosted cellular profiling technology enables us to deep dive into patient-based disease models, triggered by mutations in mechanism of actions (MOAs) that are common for specific disease indications of muscle, cardiac and CNS disorders. For each of our programs, we identify a defined patient group and associate clinical and pharmacological experts from the start to allow for the best translational concept.

Ksilink is seeking to either spin-out or partner these programs in return for upfront payments, milestones and royalties.

Our pipeline is completed by 4 additional research driven programs with support from National and EU consortia as well as patient organizations to become the next generation of drug discovery programs.